• Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy. 

  Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; Peterson, DR; Hollenberg, M; Hao, K; Narzo, AD; Ahsen, ME; Pandey, G; Bentzen, SM; Janelsins, M; Elliott, RM; Pharoah, PDP; Burnet, NG; Dearnaley, DP; Gulliford, SL; Hall, E; Sydes, MR; Aguado-Barrera, ME; Gómez-Caamaño, A; Carballo, AM; Peleteiro, P; Lobato-Busto, R; Stock, R; Stone, NN; Ostrer, H; Usmani, N; Singhal, S; Tsuji, H; Imai, T; Saito, S; Eeles, R; DeRuyck, K; Parliament, M; Dunning, AM; Vega, A; Rosenstein, BS; West, CML (2019-05-16)

  BACKGROUND: 10-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction ...
• Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer. 

  Slovin, SF; Hussain, S; Saad, F; Garcia, JA; Picus, J; Ferraldeschi, R; Crespo, M; Flohr, PR; Riisnaes, R; Lin, C; Keer, H; Oganesian, A; Workman, P; de Bono, JS (2019-05-21)

  PURPOSE: Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This Phase 1/2 trial evaluated onalespib in combination ...
• Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. 

  Craddock, C; Slade, D; De Santo, C; Wheat, R; Ferguson, P; Hodgkinson, A; Brock, K; Cavenagh, J; Ingram, W; Dennis, M; Malladi, R; Siddique, S; Mussai, F; Yap, C (2019-03-01)

  PURPOSE: Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. ...
• How to design a dose-finding study using the continual reassessment method. 

  Wheeler, GM; Mander, AP; Bedding, A; Brock, K; Cornelius, V; Grieve, AP; Jaki, T; Love, SB; Odondi, L; Weir, CJ; Yap, C; Bond, SJ (2019-01-18)

  INTRODUCTION: The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in targeting ...
• Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. 

  Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; Griffiths, B; Moorcraft, S-Y; Rana, I; Begum, R; Assiotis, I; Matthews, N; Rao, S; Watkins, D; Chau, I; Cunningham, D; Starling, N; Gerlinger, M (2019-05-27)

  DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ...
• PHOTOdynamic versus white light-guided treatment of non-muscle invasive bladder cancer: A study protocol for a randomised trial of clinical and cost effectiveness 

  Hall, E; Lewis, R; Penegar, S
• PHOTOdynamic versus white light-guided treatment of non-muscle invasive bladder cancer: A randomised trial of clinical and cost effectiveness. 

  Hall, E; Lewis, R; Penegar, S
• Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. 

  Moss, CA; Cojocaru, E; Hanwell, J; Ward, S; Xu, W; van Zyl, M; O'Leary, L; de Bono, JS; Banerji, U; Kaye, SB; Minchom, A; George, AJ; Lopez, J; McVeigh, TP (2019-06)

  BACKGROUND: Molecular aberrations in cancer may represent therapeutic targets, and, if arising from the germline, may impact further cancer risk management in patients and their blood relatives. Annually, 600-700 patients ...
• Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials 

  Boddington, C; Bradley, R; Braybrooke, J; Burrett, J; Clarke, M; Davies, C; Davies, L; Dodwell, D; Duane, F; Evans, V; Gettins, L; Godwin, J; Gray, R; Hills, R; James, S; Liu, H; Liu, Z; MacKinnon, E; Mannu, G; McGale, P; McHugh, T; Morris, P; Pan, H; Peto, R; Read, S; Taylor, C; Wang, Y; Wang, Z; Bradley, R; Braybrooke, J; Gray, R; Bergh, J; Peto, R; Gray, R; Bradley, R; Braybrooke, J; Liu, Z; Peto, R; Davies, L; Dodwell, D; McGale, P; Pan, H; Taylor, C; Barlow, W; Bliss, J; Bruzzi, P; Cameron, D; Fountzilas, G; Loibl, S; Mackey, J; Martin, M; Del Mastro, L; Moebus, V; Nekljudova, V; De Placido, S; Swain, S; Untch, M; Pritchard, KI; Bergh, J; Norton, L; Fasching, P; Harbeck, N; Untch, M; Piedbois, P; Gnant, M; Steger, G; Di Leo, A; Dolci, S; Francis, P; Larsimont, D; Nogaret, JM; Philippson, C; Piccart-Gebhart, MJ; Linn, S; Peer, P; Tjan-Heijnen, V; Vliek, S; Mackey, J; Martin, M; Slamon, D; Bartlett, JMS; Bramwell, VH; Chen, BE; Chia, SKL; Gelmon, K; Goss, PE; Levine, MN; Parulekar, W; Pater, JL; Pritchard, KI; Rakovitch, E; Shepherd, LE; Tu, D; Whelan, T; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Weiss, RB; Shan, Y; Shao, YF; Wang, X; Xu, B; Zhao, DB; Bartelink, H; Bijker, N; Bogaerts, J; Cardoso, F; Cufer, T; Julien, JP; Poortmans, PM; Rutgers, E; van de Velde, CJH; Carrasco, E; Martin, M; Segui, MA; Blohmer, JU; Costa, SD; Gerber, B; Jackisch, C; Loibl, S; Nekljudova, V; von Minckwitz, G; Bruzzi, P; Giuliano, M; De laurentiis, M; De Placido, S; Del Mastro, L; Bamia, C; Fountzilas, G; Koliou, G-A; Mavroudis, D; A'Hern, R; Bliss, J; Cameron, D; Ellis, P; Kilburn, L; Morden, J; Yarnold, JR; Sadoon, M; Tulusan, AH; Anderson, S; Bass, G; Costantino, J; Dignam, J; Fisher, B; Geyer, C; Mamounas, EP; Paik, S; Redmond, C; Swain, S; Wickerham, L; Wolmark, N; Del Mastro, L; Venturini, M; Bighin, C; Bruzzi, P; Del Mastro, L; Pastorino, S; Pronzato, P; Sertoli, MR; Barlow, W; Bergh, J; Foukakis, T; Pritchard, KI; Swain, S; Cameron, D; Albain, K; Anderson, S; Arriagada, R; Barlow, W; Bartlett, J; Bergsten-Nordstrom, E; Bliss, J; Boccardo, F; Bradley, R; Brain, E; Braybrooke, J; Carey, L; Clarke, M; Coates, A; Coleman, R; Correa, C; Costantino, J; Cuzick, J; Davidson, N; Davies, C; Davies, L; Di Leo, A; Dodwell, D; Dowsett, M; Duane, F; Ewertz, M; Forbes, J; Francis, P; Gelber, R; Gnant, M; Goldhirsch, A; Goodwin, P; Gray, R; Hayes, D; Hill, C; Ingle, J; Jagsi, R; Janni, W; Liu, Z; Loibl, S; MacKinnon, E; Mannu, G; Martin, M; McGale, P; Mukai, H; Nekljudova, V; Norton, L; Ohashi, Y; Paik, S; Pan, H; Peto, R; Piccart, M; Pierce, L; Poortmans, P; Raina, V; Ravdin, P; Rea, D; Regan, M; Robertson, J; Rutgers, E; Slamon, D; Sparano, J; Steger, G; Taylor, C; Tutt, A; Viale, G; Wang, X; Whelan, T; Wilcken, N; Wolmark, N; Wood, W; Zambetti, M; EBCTCG (2019-04-06)
• IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 

  Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; Crespo, M; De Bernardis, G; Losa, M; Mirenda, M; Pasquini, E; Rinaldi, A; Sumanasuriya, S; Lambros, MB; Neeb, A; Lucianò, R; Bravi, CA; Nava-Rodrigues, D; Dolling, D; Prayer-Galetti, T; Ferreira, A; Briganti, A; Esposito, A; Barry, S; Yuan, W; Sharp, A; de Bono, J; Alimonti, A (2018-07)

  Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control ...
• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 

  Scher, HI; Morris, MJ; Stadler, WM; Higano, C; Basch, E; Fizazi, K; Antonarakis, ES; Beer, TM; Carducci, MA; Chi, KN; Corn, PG; de Bono, JS; Dreicer, R; George, DJ; Heath, EI; Hussain, M; Kelly, WK; Liu, G; Logothetis, C; Nanus, D; Stein, MN; Rathkopf, DE; Slovin, SF; Ryan, CJ; Sartor, O; Small, EJ; Smith, MR; Sternberg, CN; Taplin, ME; Wilding, G; Nelson, PS; Schwartz, LH; Halabi, S; Kantoff, PW; Armstrong, AJ (2016-04)

  Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to ...
• Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. 

  Halabi, S; Kelly, WK; Ma, H; Zhou, H; Solomon, NC; Fizazi, K; Tangen, CM; Rosenthal, M; Petrylak, DP; Hussain, M; Vogelzang, NJ; Thompson, IM; Chi, KN; de Bono, J; Armstrong, AJ; Eisenberger, MA; Fandi, A; Li, S; Araujo, JC; Logothetis, CJ; Quinn, DI; Morris, MJ; Higano, CS; Tannock, IF; Small, EJ (2016-05)

  Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We ...
• Immunotherapy for lethal prostate cancer. 

  Rescigno, P; de Bono, JS (2019-02)
• PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. 

  Mateo, J; Carreira, S; de Bono, JS (2019-04-03)
• Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity. 

  Naismith, OF; Griffin, C; Syndikus, I; South, C; Mayles, H; Mayles, P; Khoo, V; Scrase, C; Graham, J; Hassan, S; Hall, E; Dearnaley, DP; CHHiP Investigators (2019-06-06)

  AIMS: The CHHiP (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy In Prostate Cancer; CRUK/06/016) trial investigated hypofractionated radiotherapy for localised prostate cancer. Forward- (FP) ...
• Clinical Trials From the Other Side: Lessons Learned by a Clinician Venturing Into a Clinical Trials Unit 

  Bhattacharya, IS; Bliss, JM (2019-07)
• Radiotherapy Quality Assurance for the CHHiP Trial: Conventional versus Hypofractionated High-dose Intensity-modulated Radiotherapy in Prostate Cancer 

  Hall, E; Khoo, V; Dearnaley, D
• Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. 

  Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; Seed, G; Flohr, P; Crespo, M; Figueiredo, I; Miranda, S; Scher, HI; Terstappen, LWMM; de Bono, JS (2018-07-01)

  Background: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a ...
• Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

  Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)

  Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
• Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. 

  Sharp, A; Coleman, I; Yuan, W; Sprenger, C; Dolling, D; Rodrigues, DN; Russo, JW; Figueiredo, I; Bertan, C; Seed, G; Riisnaes, R; Uo, T; Neeb, A; Welti, J; Morrissey, C; Carreira, S; Luo, J; Nelson, PS; Balk, SP; True, LD; de Bono, JS; Plymate, SR (2019-01-02)

  BACKGROUND: Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant ...

View more